{'52WeekChange': 0.0073856115,
 'SandP52WeekChange': 0.0644362,
 'address1': "21 Ha'arba'a Street",
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 6.87,
 'askSize': 800,
 'averageDailyVolume10Day': 273725,
 'averageVolume': 361095,
 'averageVolume10days': 273725,
 'beta': 1.722128,
 'beta3Year': None,
 'bid': 6.83,
 'bidSize': 1400,
 'bookValue': 1.238,
 'category': None,
 'circulatingSupply': None,
 'city': 'Tel Aviv',
 'companyOfficers': [],
 'country': 'Israel',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 6.96,
 'dayLow': 6.388,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.604,
 'enterpriseToRevenue': 40.791,
 'enterpriseValue': 228836672,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '972 3 541 3144',
 'fiftyDayAverage': 6.8705716,
 'fiftyTwoWeekHigh': 9.12,
 'fiftyTwoWeekLow': 3.262,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 20841865,
 'forwardEps': -0.02,
 'forwardPE': -341.00003,
 'fromCurrency': None,
 'fullTimeEmployees': 155,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.15365,
 'heldPercentInstitutions': 0.20913,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/redhillbio.com',
 'longBusinessSummary': 'RedHill Biopharma Ltd., a specialty biopharmaceutical '
                        'company, primarily focuses on the development and '
                        'commercialization of drugs for gastrointestinal '
                        'diseases. The company promotes various '
                        'gastrointestinal drugs, including Movantik for '
                        'opioid-induced constipation in adults; Talicia for '
                        'the treatment of Helicobacter pylori bacterial '
                        'infection in adults; and Aemcolo for the treatment of '
                        "travelers' diarrhea in adults. Its late-stage "
                        'clinical development programs include RHB-104, which '
                        "is in Phase 3 study for treating Crohn's disease; "
                        'RHB-204, with a planned pivotal Phase 3 study for '
                        'pulmonary nontuberculous mycobacteria infections; '
                        'RHB-102 (Bekinda) that is in first Phase 3 study to '
                        'treat acute gastroenteritis and gastritis, as well as '
                        'has completed Phase 2 study for treating irritable '
                        'bowel syndrome with diarrhea; RHB-106, which is in '
                        'planned Phase 2/3 studies for bowel preparation; '
                        'ABC294640 (Yeliva), a SK2 selective inhibitor, which '
                        'is in Phase 1/2a study for treating '
                        'cholangiocarcinoma, as well as in Phase 2 study for '
                        'prostate cancer; and RHB-107 that is in planned pilot '
                        'study for cholangiocarcinoma, as well as has '
                        'completed Phase 2 study for gastrointestinal and '
                        'other solid tumors. The company was founded in 2009 '
                        'and is headquartered in Tel Aviv, Israel.',
 'longName': 'RedHill Biopharma Ltd.',
 'market': 'us_market',
 'marketCap': 240538672,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_104926324',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -49591000,
 'nextFiscalYearEnd': 1640908800,
 'open': 6.61,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '972 3 541 3131',
 'previousClose': 6.56,
 'priceHint': 2,
 'priceToBook': 5.5088854,
 'priceToSalesTrailing12Months': 42.87677,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 6.96,
 'regularMarketDayLow': 6.388,
 'regularMarketOpen': 6.61,
 'regularMarketPreviousClose': 6.56,
 'regularMarketPrice': 6.61,
 'regularMarketVolume': 264087,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 35269600,
 'sharesPercentSharesOut': 0.0511,
 'sharesShort': 1801884,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1709758,
 'shortName': 'Redhill Biopharma Ltd.',
 'shortPercentOfFloat': None,
 'shortRatio': 5.91,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'RDHL',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.578,
 'twoHundredDayAverage': 6.051655,
 'volume': 264087,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.redhillbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '6473921'}